The short answer
Semaglutide is a peptide analogue of human GLP-1 sharing roughly 94% sequence homology with the native hormone. Three modifications give it a once-weekly half-life: an Aib substitution at position 8 that blocks DPP-4 cleavage, a C18 diacid chain that binds albumin, and an Arg34Lys substitution. It is marketed as Ozempic, Wegovy and Rybelsus.
Key facts
- Class
- GLP-1 receptor agonist (peptide analogue)
- Developer
- Novo Nordisk
- Molecular weight
- ~4,114 Da
- Molecular formula
- C187H291N45O59
- PubChem CID
- 56843331
- Homology to native GLP-1
- ~94%
- Half-life
- About one week
- Brands
- Ozempic, Wegovy, Rybelsus
What was changed from the natural hormone
Native GLP-1 has a half-life of one to two minutes, which makes it useless as a medicine. Semaglutide makes three changes. Alanine at position 8 is replaced with α-aminoisobutyric acid (Aib), which DPP-4 cannot cleave. Lysine 26 carries a C18 diacid chain attached through a γGlu-2xOEG linker, which binds reversibly to serum albumin and shields the peptide from renal clearance. Arginine 34 is substituted for lysine so the fatty acid attaches at a single defined site. The result is a half-life of about a week.
How albumin binding actually extends half-life
This is worth understanding because the same trick appears in liraglutide, retatrutide and most modern incretin analogues. Albumin is a large, abundant, long-lived plasma protein. A peptide bound to it is too large for glomerular filtration and is physically shielded from proteases. Because binding is reversible, a small free fraction remains available to engage the receptor at any moment, and the albumin-bound pool acts as a slow-release depot. Chain length tunes the effect: liraglutide's C16 chain gives roughly a day, semaglutide's C18 diacid gives about a week.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
The three products and why they differ
Ozempic is semaglutide for type 2 diabetes, injected weekly. Wegovy is the same molecule at higher dose for weight management. Rybelsus is oral semaglutide, co-formulated with the absorption enhancer SNAC and taken daily with dosing conditions (a fasting window and a defined water volume), because a peptide cannot otherwise survive the stomach.
SELECT and cardiovascular outcomes
The SELECT trial enrolled 17,604 participants aged 45 or over with a BMI of 27 or above, established cardiovascular disease and no diabetes, across 41 countries. Semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% against placebo, published in the New England Journal of Medicine in 2023. This mattered because it moved the class from weight reduction as an endpoint in itself to demonstrated hard-outcome benefit.
Where it sits now
Semaglutide is no longer the most effective incretin available (SURMOUNT-5 showed tirzepatide producing substantially greater reduction head-to-head), but it has by far the largest outcome-trial evidence base, and additional indications including heart failure with preserved ejection fraction and peripheral artery disease have been under regulatory review.
Frequently asked questions
Is semaglutide the same as Ozempic and Wegovy?
Yes, it is the same molecule. The brands differ by indication and dose: Ozempic for type 2 diabetes, Wegovy for weight management, Rybelsus as the oral formulation.
Why does semaglutide only need weekly dosing?
The Aib8 substitution blocks DPP-4 cleavage and the C18 diacid chain binds albumin, which together extend the half-life from minutes to about a week.
What does 94% homology mean?
That the sequence is nearly identical to human GLP-1. The differences are a small number of deliberate substitutions plus the fatty-acid attachment.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- What Is Tirzepatide? The First Dual Incretin AgonistTirzepatide is a dual GIP and GLP-1 receptor agonist built on a GIP backbone. SURMOUNT-1 reported up to 22.5% weight reduction over 72 weeks.
- Semaglutide vs Tirzepatide: What the Direct Comparison ShowedSURMOUNT-5 randomised 751 adults to tirzepatide or semaglutide for 72 weeks: 20.2% against 13.7% mean reduction. The full comparison, including tolerability.
- What Is the Incretin Effect?Oral glucose produces far more insulin than the same glucose given intravenously. That gap is the incretin effect, and this whole drug class exploits it.
- DPP-4: Why Native Incretins Last Two MinutesDPP-4 removes two residues from GLP-1 and inactivates it within minutes. How Aib8 substitution and albumin binding defeat it, and why small molecules ignore it.
- GLP-1 Drugs Beyond Weight LossSELECT showed a 20% reduction in cardiovascular events. Heart failure, kidney and peripheral artery indications followed. What the evidence supports.